Compound Information | SONAR Target prediction |
Name: | APOMORPHINE HYDROCHLORIDE |
Unique Identifier: | SPE01500129 |
MolClass: | Checkout models in ver1.5 and ver1.0 |
Molecular Formula: | |
Molecular Weight: | 285.64 g/mol |
X log p: | 11.212 (online calculus) |
Lipinksi Failures | 1 |
TPSA | 3.24 |
Hydrogen Bond Donor Count: | 0 |
Hydrogen Bond Acceptors Count: | 3 |
Rotatable Bond Count: | 0 |
Canonical Smiles: | Cl.CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c13 |
Source: | synthetic |
Therapeutics: | emetic |
Generic_name: | Apomorphine |
Drug_type: | Approved Drug |
Drugbank_id: | APRD00531 |
H2o_solubility: | 1.66E+004 mg/L |
Logp: | 3.03 |
Isoelectric_point: | 8.92 |
Cas_registry_number: | 41372-20-7 |
Drug_category: | Antiparkinson Agents; Dopamine Agonists; Antidyskinetics; ATC:G04BE07; ATC:N04BC07 |
Indication: | For the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) associated with advanced Parkinson-s disease. |
Pharmacology: | Apomorphine is a type of dopaminergic agonist, a morphine derivative which primarily affects the hypothalamic region of the brain. Drugs containing this substance are sometimes used in the treatment of Parkinson-s disease or erectile dysfunction. In higher doses it is a highly effective emetic. |
Mechanism_of_action: | The precise mechanism of action of apomorphine as a treatment for Parkinson-s disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D2-type receptors within the brain. Apomorphine has been shown to improve motor function in an animal model of Parkinson-s disease. In particular, apomorphine attenuates the motor deficits induced by lesions in the ascending nigrostriatal dopaminergic pathway with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in primates. |
Organisms_affected: | Humans and other mammals |